Locally Advanced Pancreatic Cancer

Also known as: Pancreatic Carcinoma Stage II / Locally advanced Pancreatic cancer

DrugDrug NameDrug Description
DB00530ErlotinibErlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
DrugDrug NamePhaseStatusCount
DB01101Capecitabine1 / 2Completed1
DB00441Gemcitabine1 / 2Completed1
DB00441Gemcitabine1 / 2Not Yet Recruiting1
DB00441Gemcitabine1 / 2Recruiting1
DB00526Oxaliplatin1 / 2Completed1
DB00530Erlotinib2Completed1
DB00544Fluorouracil2Unknown Status1
DB00441Gemcitabine2Completed2
DB00441Gemcitabine2Unknown Status2
DB00650Leucovorin2Unknown Status1
DB05477MUC1 Dendritic Cell Vaccine2Withdrawn1
DB00331Metformin2Completed1
DB00526Oxaliplatin2Completed1
DB00526Oxaliplatin2Unknown Status1
DB06361rsPSMA Vaccine2Withdrawn1
DB00758Clopidogrel3Active Not Recruiting1
DB00441Gemcitabine3Completed1
DB00441Gemcitabine3Recruiting1
DB00762Irinotecan3Recruiting1
DB00441Gemcitabine4Recruiting1
DB01229Paclitaxel4Recruiting1
DB00441GemcitabineNot AvailableRecruiting1